Esperion Therapeutics, Inc. stock is up 42.77% since 30 days ago. The next earnings date is Feb 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 November’s closed higher than October. In the last 1 Unusual Options Trades, there were 1 PUT. 67% of analysts rate it a buy.
Esperion Therapeutics, Inc. develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.